Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix's Q3 Revenues Increase 4 Percent; Shares Sink on Estimates Miss

NEW YORK (GenomeWeb News) – Affymetrix reported after the close of the market Wednesday that its third-quarter revenues increased 4 percent while its net loss fell sharply.

However, its top- and bottom-line results missed analysts' consensus estimates. In early Thursday trade on the Nasdaq, Affy's shares traded down 18 percent at $7.25.

The Santa Clara, Calif.-based firm reported total revenues of $78.2 million for the three-month period ended Sept. 30, up from $75.2 million for the third quarter of 2008. Analysts, on average, had expected revenues of $80.7 million.

Affy's product sales grew to $66.2 million from $66 million year over year, while service revenues rose sharply to $9.9 million from $6.1 million. Its royalties and other revenues dropped to $2.1 million from $3.1 million.

The vast majority of its product revenue came from consumables sales, which were $62 million for the quarter. The firm shipped 21 instrument systems during Q3, bringing its cumulative systems shipped to around 1,890.

Kevin King, Affymetrix's CEO, said during a conference call that the firm is targeting sales of 35 GeneTitan systems for 2009.

Affy's net loss dropped to $8.8 million, or $.13 per share, compared to a net loss of $31.8 million, or $.46 per share, for the third quarter of 2008. Last year's results included charges of $5.1 million for acquired in-process technology and $14.6 million in restructuring charges.

On an adjusted basis, its EPS for the quarter was $.10, missing the consensus estimate of $.09.

Affy's R&D spending dropped to $18.8 million from $20.8 million, while its SG&A expenses increased to $30.6 million from $28.4 million.

The firm finished the quarter with $62.5 million.

Affy officials said during the call that the firm expects fourth-quarter revenues of between $82 million and $85 million.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.